Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) Gross Margin (2020 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Gross Margin for 10 consecutive years, with 54.2% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin fell 465.0% year-over-year to 54.2%, compared with a TTM value of 54.87% through Dec 2025, up 721.0%, and an annual FY2025 reading of 56.51%, up 2525.0% over the prior year.
  • Gross Margin was 54.2% for Q4 2025 at Neuroone Medical Technologies, down from 55.77% in the prior quarter.
  • Across five years, Gross Margin topped out at 58.85% in Q4 2024 and bottomed at 115.81% in Q1 2021.
  • Average Gross Margin over 5 years is 4.76%, with a median of 26.67% recorded in 2023.
  • The sharpest move saw Gross Margin skyrocketed 10577bps in 2023, then crashed -465bps in 2025.
  • Year by year, Gross Margin stood at 38.81% in 2021, then surged by 72bps to 10.74% in 2022, then soared by 354bps to 27.24% in 2023, then soared by 116bps to 58.85% in 2024, then fell by -8bps to 54.2% in 2025.
  • Business Quant data shows Gross Margin for NMTC at 54.2% in Q4 2025, 55.77% in Q3 2025, and 53.94% in Q2 2025.